Search

"There's 145 components of the regulatory requirements that I don't fit in. So how do I get past that? And governments right now say, I don't know." "Phages are not drugs. Every time they say, 'Did you go through regulatory?' I say, 'I can

"We put a dent in the theory that phage therapy doesn't work. Maybe it does work. Maybe it's worth taking a risk." This week we talk to Jonathan Solomon, CEO of BiomX, about their successful phase 2 clinical trial for diabetic foot osteomye

Roundup time! This month, we heard from Aaryan's experience as an undergrad researcher at Paul Bollyky's lab. We picked papers across topics like T4-AAV viral vectors, cell-free synthesis of phages, and taxMyPhage, a new tool for classifyin

"As soon as investors hear 'infectious disease,' their eyes get big. When they hear 'antibacterial,' alarm bells start ringing.” And yet, Amanda Burkardt and Mayukh Das are building Phiogen Pharmaceuticals anyway. Why? We’ve all heard about

Issue #300! This month we announced the return of Evergreen, covered Intralytix's 25-year-long overnight success, and Silvia's journey to build up a new phage lab. Hi phage phans, Look at that, we’re on Issue 300! That’s a really big numbe

"Phages? We don't use those here." This week, learn how these words propelled Sandro Sulakvelidze, fresh from phage-friendly Tbilisi, into a 25+ year journey to build a phage company with FDA-approved products. From a chance conversation ab

This month, we heard about PHIOGEN, a new phage startup, about how the phage therapy system works at Phage Australia, and about a biobank data platform we're building at Phage Australia. Alright everyone, just about a week away from Evergre

This week Amanda Burkardt, CEO of the new phage therapy company, PHIOGEN (a spinoff of Baylor College of Medicine and based on the innovations of TAILOR Labs) shares their plans for the company. ## A Global Vision of an Infection-free Human

Adam Yang, an intern at Shanghai Institute of Phage, interviewed the co-founder of CreatiPhage, Nannan Wu. CreatiPhage is the first company applying phage therapy to humans in China, and seeks to promote the overall development of phage the

This month, we wrote an article for GARDP about phage therapy business models. For this issue, we're also revisiting a couple of gems from Dr. Paul Jaschke's lab! Hey look, we’re almost 10% into 2023! And we’ve barely written anything this

This week, Ruby CY Lin of Phage Australia dives further into commercialization pathways and opportunities for Phage Australia, and the phage industry as a whole. Welcome back to the third installment of the Sustainable Phage Therapy serie

This week, Ruby CY Lin of Phage Australia dives further into commercialization pathways and opportunities for Phage Australia, and the phage industry as a whole. In Part Two of this three-part series, she explores possible phage therapy in

This week, we highlight our October feature articles: Dive down the rabbit hole with us on designing phage data systems, building sustainable phage therapy, and get excited for this year's World Phage Week! Here's what we published this mon

This week, Ruby CY Lin of Phage Australia dives deep into commercialization pathways and opportunities for Phage Australia, and the phage industry as a whole. In Part One of this three-part series, she explains the importance of phage manu

This week Madhav Madurantakam Royam, a PhD student at the University of Warwick, talks to Dr. Alexander Sulakvelidze, founder and CEO of Intralytix, one of the first modern phage companies to have products on the market. This week Madhav Ma

This week, McMaster University PhD student Kyle Jackson interviews Cytophage and BiomX executives, who share phage therapy commercialization challenges and progress and a sneak peek into what they'll present at Phage Futures. You can also

This week, Kyle Jackson (PhD student at McMaster University) brings us a profile of Adaptive Phage Therapeutics, the clinical-stage phage biotech company commercializing the US Navy's phage collection. This is the first in a new column Kyle

This week, we're featuring a guest blog post by David Sáez and Lorenzo Corsini of PhagoMed; they dive into their recent paper describing how they're breeding phages to be better for therapy using a modified Appelman's protocol. Read our rec

What brought phage therapy to where it is today? This week, we're featuring an interview with Dr. David Harper, CEO of Evolution Biotechnologies, by Curtis Hoffmann, a longtime Phage Directory volunteer. They discuss David's thoughts on his

We attended Kisaco Research's Phage Futures Congress 2021 at the end of February, and now present our recap of the event. We hope to provide a window into what you missed, and/or a refresher if you were there! The third annual Phage Futures